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DNA hypomethylating agents (DHAs) play a well-acknowledged role in potentiating the
immunogenicity and the immune recognition of neoplastic cells. This immunomodulatory
activity of DHAs is linked to their ability to induce or to up-regulate on neoplastic
cells the expression of a variety of immune molecules that play a crucial role in
host-tumor immune interactions. To further investigate the clinical potential of diverse
epigenetic compounds when combined with immunotherapeutic strategies, we have
now compared the tumor immunomodulatory properties of the first generation DHAs,
azacytidine (AZA) and decitabine (DAC) and of the next generation DHA, guadecitabine.
To this end, human melanoma and hematological cancer cells were treated in vitro with
1 µM guadecitabine, DAC or AZA and then studied by molecular and flow cytometry
analyses for changes in their baseline expression of selected immune molecules involved
in different mechanism(s) of immune recognition. Results demonstrated a stronger
DNA hypomethylating activity of guadecitabine and DAC, compared to AZA that
associated with stronger immunomodulatory activities. Indeed, the mRNA expression
of cancer testis antigens, immune-checkpoint blocking molecules, immunostimulatory
cytokines, involved in NK and T cell signaling and recruiting, and of genes involved
in interferon pathway was higher after guadecitabine and DAC compared to AZA
treatment. Moreover, a stronger up-regulation of the constitutive expression of HLA class
I antigens and of Intercellular Adhesion Molecule-1 was observed with guadecitabine
and DAC compared to AZA. Guadecitabine and DAC seem to represent the optimal
combination partners to improve the therapeutic efficacy of immunotherapeutic agents
in combination/sequencing clinical studies.
Keywords: DNA hypomethylating agent, epigenetics, cancer, immune phenotype, immunotherapy
INTRODUCTION
Epigenetic events are emerging as a hallmark of cancer development and progression, impairing
immunogenicity and immune recognition of cancer cells, possibly favoring their escape from the
host’s immune recognition (Sigalotti et al., 2005; Maio et al., 2015). One of the most widely studied
epigenetic modifications in cancer is the aberrant methylation of DNA. It could occur through
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both global DNA hypomethylation, leading to genomic instability
and possibly increasing the frequency of mutations and
chromosomal abnormalities (Howard et al., 2008; Pogribny,
2010), and through the hypermethylation of specific genes
leading to the impairment of the corresponding protein
expression, mainly catalyzed by DNA methyltransferase (DNMT)
enzymes (Sigalotti et al., 2014). The plasticity of epigenetic
phenomena suggested the feasibility of their targeting by
epigenetic drugs, such as DNA hypomethylating agents (DHAs),
that can restore the physiologic epigenetic pattern by targeting
DNMT enzymes (Maio et al., 2015). The most studied DHAs
are nucleoside analogs of cytidine in which the cytosine ring
has been modified to give them the DNMT inhibitory activity
(Yoo and Jones, 2006). They include the first generation DHAs,
azacytidine (AZA) and decitabine (DAC), FDA approved for
the treatment of myelodysplastic syndromes (MDS) and acute
myeloid leukemia (AML) (Saba, 2007; Cataldo et al., 2009),
and the next generation DHA, guadecitabine. The latter is
a dinucleotide of decitabine and deoxyguanosine designed to
protect its active metabolite, DAC, from cytidine deaminase
degradation resulting in a higher stability and a better tolerability
of DAC in cancer patients (Yoo et al., 2007; Issa et al., 2015;
Jueliger et al., 2016).
We have extensively demonstrated an epigenetic remodeling
of cancer by DAC and guadecitabine as a result of the
up-regulation and induction of different immune molecules
and antigens involved in the immunogenicity and/or immune
recognition of cancer cells of different histotype. Among them,
HLA class I antigens, the co-stimulatory molecule ICAM-1,
and tumor-associated antigens (TAA), such as the cancer testis
antigens (CTAs) NY-ESO-1 and MAGE-A3 that are considered
suitable therapeutic targets due to their high immunogenic
potential (Coral et al., 1999, 2013). The functional role of
these phenotypic changes is demonstrated by the significant
improvement of tumor cells recognition by CTA-specific
cytotoxic T lymphocytes (CTL) (Sigalotti et al., 2004) and by the
induction of anti-CTA humoral immune response in vivo (Coral
et al., 2006).
Besides an activity on genes directly involved in the
recognition of tumor cell by T lymphocytes, transcriptional
changes induced in tumors by DHAs affected also several
genes involved in the viral defense pathway, leading to an
“indirect” activation of anti-tumor immune response through
the modulation of interferon (IFN) signaling (Chiappinelli et al.,
2017).
Epigenetic remodeling has been also demonstrated to sensitize
cancer cells to immune checkpoint (IC) blocking therapies,
through the up-regulation of immunostimulatory cytokines [e.g.,
chemokine ligand 9 (CXCL9) and 10 (CXCL10)] that recruit
T lymphocytes at tumor sites (Dunn and Rao, 2017), and/or
through the up-regulation of the expression of IC molecules [i.e.,
cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death
receptor 1 (PD-1) and its ligands (PD-L1 and PD-L2)] in MDS
(Yang et al., 2014).
Innate immune cells play an important role in inhibiting
cancer progression by complementing the effector activities of
T cells; it has been demonstrated that these cells could exploit the
action of epigenetic drugs by increasing tumor cell recognition
and immune-mediated cell lysis. In this context, several studies
reported that DAC-mediated hypomethylation could restore the
NK group 2D ligands (NKG2DLs) [e.g., MHC class I–related
chains (MIC) A and B] expression in tumors that represent
an activating and a costimulatory signal for NK and T cells,
respectively (Vasu et al., 2016; Zhang et al., 2016).
Although during the last years the pleiotropic
immunomodulatory properties of different DHAs are
consolidating, to the best of our knowledge no study investigated
the differences among their activity. With the aim to optimize
the therapeutic efficacy of DHAs in clinical setting and to
identify the best epigenetic partner to be combined with cancer
immunotherapy, we performed a comparative study of the
immunomodulatory properties of the clinically approved
DHAs (i.e., AZA and DAC) and of the next generation DHA
guadecitabine, mainly focusing on the expression of different
genes involved in different mechanism(s) of anti-tumor
immunity.
MATERIALS AND METHODS
Cell Lines
Human cutaneous melanoma cell lines (Mel 195, 275, 313,
346, 116, 120, 514, 142, 237, 403, 458, 345, 599, and 261)
were generated from surgically removed metastatic lesions from
melanoma patients, as previously described (Altomonte et al.,
1993). Human hematological cancer cell lines (Daudi, HL-60,
NALM-6, Raji, U-937, KG-1a, Jurkat, JY, Ri-1, K562) were
purchased from American Type Culture Collection (Rockville,
MD, United States).
Melanoma cells were grown in RPMI 1640 (Carlo Erba,
Milan, Italy) supplemented with 10% heat-inactivated FBS
(Biochrom, Berlin, Germany) and 2 mM L-glutamine (Biochrom,
Berlin, Germany). Hematological tumor cell lines were grown
in ISCOVE Basal Medium (Biochrom, Berlin, Germany)
supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine
and 100 µg/µl penicillin/streptomycin (Biochrom, Berlin,
Germany).
Monoclonal Antibodies and Reagents
PE Mouse anti-human ICAM-1 clone 84H10 monoclonal
antibody (mAb) was purchased from Beckman Coulter;
alexafluor 488 mouse anti-human HLA class I clone W6/32
mAb was purchased from Biolegend; guadecitabine was kindly
provided by Astex Pharmaceuticals, Inc. (Pleasanton, CA,
United States); DAC was purchased from Abcam and AZA from
Sigma Chemical Co.
In vitro Tumor Cells Treatment With
DHAs
Human melanoma (1 × 106) and hematological cancer
(1,2 × 106) cell lines were seeded in T75 tissue culture flasks and
treated 24 h later with 1 µM dose of guadecitabine or DAC (Coral
et al., 2013), compared to an equimolar dose of AZA every 12 h
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for 2 days (4 pulses). At the end of the treatment (day 6th), cell
lines were collected and analyzed. Control cultures were treated
under similar experimental conditions without drugs.
Quantitative Real-Time Methylation
Specific PCR (qMSP) Analysis
Genomic DNA (500 ng) extracted from melanoma cell lines,
using QIAmp DNA Blood mini Kit (Qiagen, Hilden, Germany),
was subjected to modification with sodium bisulfite using
the EZ DNA Methylation-Gold Kit (Zymo Research, CA,
United States). Primers for the analysis of the methylation
status of LINE-1 were designed using the free on-line software
MethPrimer (Li and Dahiya, 2002), and are the follows: LINE-
1 Unmethylated F: 5′-TGTGTGTGAGTTGAAGTAGGGT-3′,
Unmethylated R: 5′-ACCCAATTTTCCAAATACAACCATCA-
3′; LINE-1 Methylated F: 5′-CGCGAGTCGAAGTAGGGC-3′,
Methylated R: 5′-ACCCGATTTTCCAAATACGACCG-3′. SYBR
green qMSP reactions were performed with methylated- or
unmethylated-specific primer pairs on 2 µl of bisulfite-modified
genomic DNA. The copy number of methylated or unmethylated
sequences for LINE-1 gene was established by extrapolation
from the standard curves. The percentage (%) of methylation
was defined as ratio between methylated molecules and the
sum of methylated and unmethylated molecules and data were
reported as % of LINE-1 demethylation ± standard deviation
(SD) of treated vs. untreated cells. CpG Methyltransferase (New
England BioLabs, Ipswich, MA, United States) and RepliG
mini Kit (Qiagen, Hilden, Germany) were used to obtained
positive (CTRL +) and negative (CTRL −) methylation control,
respectively.
Quantitative Real-Time RT-PCR Analysis
Total RNA was extracted by using Trizol reagent (Invitrogen,
Milan, Italy) according to the manufacturer’s instruction.
RNA extracted was digested with RNAse-free DNAse (Roche
Diagnostics, Milan, Italy). Synthesis of cDNA was performed
on 2 µg of total RNA using M-MLV reverse transcriptase
(Invitrogen, Milan, Italy) and random hexamer primers
(Promega, Milan, Italy), according to the manufacturer’s
instructions. cDNA standards were obtained by RT-PCR
amplification of the specific mRNAs and quantitated by
NanoDrop2000 Spectrophotometer (Thermo Scientific,
Massachusetts, United States). Quantitative real time RT-
PCR were performed on 20 ng retrotranscribed total RNA
in a final volume of 20 µl SYBR Green Master Mix (Applied
Biosystems, Foster City, CA, United States) utilizing the 7500
Fast Real-Time PCR System (Applied Biosystems, Foster City,
CA, United States) and software. The copy number of specific
antigen and of the reference gene β-actin was established in
each sample by extrapolation of the standard curve. The number
of selected antigen cDNA molecules in each sample was then
normalized to the number of cDNA molecules of β-actin.
Gene expression was considered: (i) positive if numbers of
gene/β-actin molecules were ≥ 1E-04; (ii) up-regulated if its
positive expression was increased at least twice [Fold Change
(FC) ≥2]. Data analyzed by multiparametric Dunn’s test with
p < 0.05 were considered statistically significant. The primers
used for the quantitative real-time RT-PCR analyses are listed in
Supplementary Table 1.
RT-PCR Analysis
RT-PCR reactions, using oligonucleotide primer sequences and
PCR amplification programs specific for CTA family genes (i.e.,
MAGE-A2, -A4, -A10, GAGE1-2, SSX1-2, and SSX1-5), were
performed as previously described (Sigalotti et al., 2004). The
integrity of RNA and random primers-synthesized cDNA was
confirmed by the amplification of all cDNA samples with β-actin-
specific primers (Sigalotti et al., 2004). Five microliters of each
RT-PCR sample were run on a 2% agarose gel, stained with green
gel plus (Fisher Molecular Biology, Rome, Italy) and visualized by
Gel doc XR (Bio-Rad Laboratories, Hercules, CA, United States).
The primer sequences used for the quantitative RT-PCR are listed
in Supplementary Table 2.
Multi-Color Flow Cytometry
Cell surface expression of antigens on melanoma cell lines,
treated and untreated with DHAs, was assessed by direct
immunofluorescence staining followed by flow cytometry
utilizing FACSCantoTM (Beckman Coulter, Brea, CA,
United States), according to the manufacturer’s instructions.
Data were analyzed with the Kaluza software (Beckman Coulter,
Brea, CA, United States). Results were expressed as % of
positive cells and mean fluorescence intensity (MFI) values were
subtracted from unstained cells values.
Quantitative Relative Real-Time RT-PCR
Analysis
Relative quantitative real time RT-PCR of Human Endogenous
Retroviruses (HERV) Syncytin-1, -2, ERV9-1, ENV-MER34,
ENV-Fb1, ENV-Fc2, ERV-FXA34, and ENV-T were performed
on 20 ng retrotranscribed total RNA in a final volume of
20 µl SYBR Green Master Mix utilizing the 7500 Fast Real-
Time PCR System and software. Interferon stimulated genes
(ISG) were chosen from Taqman Gene Expression Assay
(Applied Biosystem, Foster City, CA, United States): DDX58
(ID Hs01061436_m1), IFIT1 (ID Hs03027069_s1), IFIT2
(ID Hs01922738_s1), STAT1 (ID Hs01013996_m1), IFI27
(ID Hs01086373_g1), IFI6 (ID Hs00242571_m1), OAS1
(ID Hs00973637_m1), OAS2 (ID Hs00942643_m1), IRF7
(ID Hs01014809_g1), IRF9 (ID Hs00196051_m1), IFITM1
(ID Hs00705137_s1), IFITM3 (ID Hs03057129_s1), MX1
(ID Hs00895608_m1), MX2 (ID Hs01550811_m1), ISG15
(ID Hs01921425_s1), ISG20 (ID Hs00158122_m1), IFI44
(ID Hs00951349_m1), IFI44L (ID Hs00915292_m1), OASL
(ID Hs00984387_m1), JAK1 (Hs01026983_m1), and JAK2
(Hs01078136_m1). The analyses were performed on 20 ng
retrotranscribed total RNA in a final volume of 20 µl TaqMan
Fast Advanced Master Mix (Applied Biosystem, Foster City, CA,
United States) utilizing the 7500 Fast Real-Time PCR System
and software. The 2−11CT method was used to calculate relative
expression levels. Results were expressed as FC of treated vs.
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FIGURE 1 | qMSP analysis of the methylation status of LINE-1 promoter in melanoma and hematological tumor cell lines treated with DHAs. Genomic DNA was
extracted from 14 melanoma (A) and 10 hematological tumor (B) cell lines treated with 1 µM guadecitabine (gray), DAC (pink) or AZA (green). Real-time qMSP
analyses of LINE-1 promoter were performed on bisulfite modified genomic DNA using methylated- or unmethylated-specific primer pairs. Data are reported as
mean values ± SD of % of LINE-1 demethylation in DHAs-treated vs. untreated cells.
untreated cells and gene expression was considered up-regulated
when its positive expression was increased at least twice (FC≥2).
RESULTS
Comparative Analysis of the
Demethylating Activity of Different DHAs
in Human Cancer Cell Lines
To compare the demethylating activity of the different
investigated DHAs in cancer cells, qMSP analysis was performed
to measure the extent of LINE-1 methylation repetitive elements,
chosen as a surrogate of the overall genomic DNA methylation,
in 14 melanoma and in 10 hematological tumor cell lines treated
with 1 µM guadecitabine, DAC or AZA.
In melanoma and hematological tumor cell lines, the highest
average global demethylation was observed after guadecitabine
treatment. In detail, the mean of LINE-1 demethylation ± SD in
guadecitabine- compared to DAC- and AZA-treated melanoma
cells were: 19.2% (ranged from 40.5 to 1%) ± 12.6% vs. 14%
(ranged from 36.1 to 0.3%) ± 10.9% and 14.3% (ranged from 35
to 0.6%) ± 8.5%, respectively (Figure 1A). In guadecitabine- vs.
DAC- and AZA-treated hematological cancer cell lines, the mean
of LINE-1 demethylation ± SD were: 43% (ranged from 67 to
13.4%) ± 17.3% vs. 33% (ranged from 60.8 to 7.2%) ± 20.6%
and 39.2% (ranged from 72.6 to 8.4%) ± 26.7%, respectively
(Figure 1B).
Comparative Analysis of CTAs
Expression in Human Cancer Cell Lines
Treated With Different DHAs
Quantitative real-time RT-PCR analyses were performed to
investigate and compare levels of CTA (i.e., NY-ESO-1, MAGE-
A3, and MAGE-A1) expression induced by the different DHAs
treatments, in CTA-negative tumor cells selected among the
investigated 14 human melanoma and 10 human hematological
cancer cell lines. A de novo expression of NY-ESO-1, MAGE-
A3 and -A1 was induced by guadecitabine or DAC treatment in
91.6% (11/12) (Figure 2A), 100% (2/2) (Figure 2B) and 100%
(3/3) (Figure 2C) of CTA-negative melanoma cells, respectively.
Conversely, a lower frequency of CTAs induction was observed
following exposure to AZA resulting in a de novo expression
of NY-ESO-1 and MAGE-A1 in 41.6% (5/12) (Figure 2A)
and 66.6% (2/3) (Figure 2C) CTA-negative melanoma cells,
respectively. The induction of MAGE-A3 was detected in 100%
(2/2) of melanoma cells treated with AZA (Figure 2B). In
addition, levels of CTAs expression, induced in melanoma cells,
was stronger after treatment with guadecitabine or DAC vs. AZA,
being the mean values of CTAs molecules± SD 1.27E-02± 3.4E-
02 and 1.09E-02 ± 2.73E-02 vs. 2.74E-03 ± 3.83E-03 for
NY-ESO-1/β-actin (Figure 2A); 6.34E-04 ± 2.91E-04 and 6.45E-
04 ± 3.47E-04 vs. 1.29E-04 ± 7.92E-06 for MAGE-A3/β-actin
(Figure 2B); 1.29E-03 ± 1.33E-03 and 1.13E-03 ± 1.04E-03
vs. 3.19E-04 ± 2.88E-04 for MAGE-A1/β-actin (Figure 2C),
respectively. Moreover, treatment with guadecitabine or DAC vs.
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FIGURE 2 | Quantitative RT-PCR analysis of CTAs expression in melanoma and hematological tumor cell lines treated with DHAs. Total RNA was extracted from
CTA-negative melanoma and hematological tumor cell lines, either untreated (CTRL) or treated with 1 µM guadecitabine, DAC or AZA every 12 h for 2 days.
Quantitative RT-PCR analyses were performed on retrotranscribed total RNA, utilizing NY-ESO-1-, MAGE-A3-, MAGE-A1- and β-actin-specific primers. CTAs
expression was normalized to the expression of the β-actin gene. Scatter plots represent the number of NY-ESO-1, MAGE-A3 and -A1 molecules induced in
melanoma (A–C) and hematological tumor (D–F) cells untreated and treated with investigated DHAs. Figures show also mean values ± SD of normalized CTAs
molecules and p value calculated by Dunn’s test between DHAs-treated compared to untreated CTA-negative cells. Each data point represents individual cell line.
Solid line (black) represents gene expression value ≥1E-04.
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AZA up-regulated (FC ≥2) the mRNA expression of NY-ESO-
1 in 100% (2/2) and 100% (2/2) vs. 50% (1/2); of MAGE-A3 in
8.3% (1/12) and 16.7% (2/12) vs. 8.3% (1/12) and of MAGE-A1 in
27.3% (3/11) and 54.5% (6/11) vs. 36.3% (4/11) in CTA-positive
melanoma cell lines (Supplementary Tables 3–5).
Small differences in the induction of CTAs expression by
investigated DHAs were also observed in hematological cancer
cell lines. In fact, treatment with guadecitabine or DAC vs. AZA
induced the expression of NY-ESO-1 in 100% (10/10), 100%
(10/10) vs. 80% (8/10) (Figure 2D), of MAGE-A3 in 100%
(9/9), 100% (9/9) vs. 77.8% (7/9) (Figure 2E) and of MAGE-
A1 in 77.8% (7/9), 88.9% (8/9) vs. 77.8% (7/9) (Figure 2F)
CTA-negative hematologic cancer cell lines, respectively. No
differences in the up-regulation (FC ≥2) of MAGE-A3 and
MAGE-A1 were observed in CTA-positive hematological tumor
cells among all investigated DHAs treatments (Supplementary
Tables 7, 8).
Statistical analysis performed on data obtained from all
(n = 14) investigated melanoma cells showed significant
differences in levels of NY-ESO-1 (p < 0.0001) and MAGE-A1
(p< 0.05) expression detected after treatment with guadecitabine
and DAC, but not with AZA, vs. untreated cells (Supplementary
Tables 3, 5). No significant changes were observed for MAGE-A3
expression in all DHAs-treated melanoma cells (Supplementary
Table 4). Data from all (n = 10) investigated hematological
cancer cells showed significant (p < 0.05) differences in levels
of NY-ESO-1 and MAGE-A1 expression after treatment with all
DHAs, compared to untreated cells (Supplementary Tables 6, 8).
Statistically significant (p < 0.005) differences in levels of
MAGE-A3 expression were observed only in guadecitabine- and
DAC-treated, compared to untreated hematological cancer cells
(Supplementary Table 7).
The immunomodulatory activity of different DHAs on
additional CTAs expression (i.e., MAGE-A2, -A4, -A10, GAGE1-
2, SSX1-2, and SSX1-5) was investigated also by RT-PCR analysis
in 14 melanoma and 10 hematological cancer cell lines treated
with 1 µM guadecitabine, DAC or AZA. In melanoma cell
lines, guadecitabine and DAC vs. AZA treatment induced the
expression of MAGE-A2 in 100% (3/3) and 66.6% (2/3) vs. 33.3%
(1/3); of MAGE-A4 in 66.6% (8/12) and 66.6% (8/12) vs. 25%
(3/12); of MAGE-A10 in 42.8% (3/7) and 42.8% (3/7) vs. 42.8%
(3/7); of GAGE1-2 in 100% (6/6) and 100% (6/6) vs. 83.3%
(5/6); of SSX1-2 in 76.9% (10/13) and 76.9% (10/13) vs. 38.4%
(5/13) and of SSX1-5 in 100% (10/10) and 100% (10/10) vs. 70%
(7/10) (Table 1). Conversely, no differences in additional CTAs
induction were observed among different DHAs treatments in
hematological cancer cell lines (data not shown).
Comparative Analysis of HLA Class I
Antigens and Co-stimulatory Molecules
Expression in Human Cancer Cell Lines
Treated With Different DHAs
The immunomodulatory activity of different DHAs on the
constitutive expression levels of HLA class I antigens and the co-
stimulatory molecule, ICAM-1, was evaluated in 14 melanoma
cell lines and 10 hematological cancer cell lines treated with 1 µM
guadecitabine, DAC or AZA, by flow cytometry.
Results showed that treatment with DHAs modulated the
constitutive expression of both antigens in all investigated
melanoma and hematological cancer cell lines. In detail, in
untreated vs. guadecitabine-, DAC- or AZA-treated melanoma
cells, mean values of MFI ± SD of HLA class I antigens were
100.60 ± 103.15 vs. 153.40 ± 130.17, 155.80 ± 126.63 and
116.30 ± 107.67 and mean values of MFI ± SD of ICAM-1 were
45.80 ± 37.81 vs. 64.50 ± 38.94, 64.8 ± 45.25 and 45.70 ± 36.56
(Table 2). In hematological cancer cell lines mean values of
MFI ± SD of HLA class I antigens were 116.80 ± 117.90 vs.
311.80± 243.50, 313.30± 248.30 and 215.50± 182.40 and mean
values of MFI ± SD of ICAM-1 molecules were 64.10 ± 70.60
vs. 202.90 ± 253.20, 205.80 ± 243.70 and 158.40 ± 196.20,
in untreated vs. guadecitabine-, DAC- or AZA-treated cells,
respectively (Table 3).
Statistical analysis performed on data obtained from all
investigated 14 melanoma and 10 hematological cancer cells
showed significant (p < 0.05) differences in MFI of HLA
class I and ICAM-1 expression detected after treatment with
guadecitabine and DAC, but not with AZA, vs. untreated cells
(Tables 2, 3).
No differences in the % of HLA class I antigens and
ICAM-1 positive cells were observed after DHAs treatment, in all
investigated melanoma and hematological tumor cell lines (data
not shown).
Comparative Analysis of IC Molecules
Expression in Human Cancer Cell Lines
Treated With Different DHAs
Quantitative real-time RT-PCR analyses were performed to
study the effects of treatment with different DHAs on the
expression levels of IC (i.e., CTLA-4, PD-1 and PD-L1) mRNA
molecules, in IC-negative cancer cells, selected among the
investigated 14 melanoma and 10 hematological cancer cell lines.
A de novo expression of CTLA-4 was induced in 71.4% (5/7)
and 85.7% (6/7) vs. 42.8% (3/7) IC-negative melanoma cells,
treated with guadecitabine and DAC vs. AZA, respectively, with
mean values ± SD of CTLA-4 molecules 1.16E-03 ± 1.73E-03
and 1.44E-03 ± 2.49E-03 vs. 2.31E-04 ± 1.07E-04, respectively
(Figure 3A). Consistent with a different immunomodulatory
activity between investigated DHAs, treatment of CTLA-4-
positive melanoma cells with guadecitabine, DAC or AZA up-
regulated (FC ≥2) the constitutive expression levels of CTLA-4
in 42.8% (3/7), 71.4% (5/7) and 28.6% (2/7) melanoma cell
lines, respectively (Figure 3B). A de novo induction of PD-1
was detected in 28.5% (4/14) and 42.8% (6/14) vs. 7.1% (1/14)
melanoma cells treated with guadecitabine or DAC vs. AZA,
respectively, with no differences in the mean values of PD-1
molecules induced by all DHAs treatments (Figure 3C).
A positive expression of PD-L1-specific mRNA was detected
in all investigated melanoma cells, and it was up-regulated
(FC ≥ 2) with a higher frequency in melanoma cells treated with
guadecitabine (50%, 7/14) or DAC (50%, 7/14), compared to AZA
(21.4%, 3/14) (Figure 3D).
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TABLE 1 | RT-PCR analysis of CTAs expression in DHAs-treated melanoma cell lines∗.
CTAs MAGE-A2 MAGE-A4 MAGE-A10 GAGE1-2 SSX1-2 SSX1-5
Mel 346 CTRL ++a − − + − −
Guadecitabine ++ + + ++ ++ ++
DAC ++ + + ++ + ++
AZA ++ − + ++ + +
Mel 116 CTRL ++ − ++ − − −
Guadecitabine ++ ++ ++ + − +
DAC ++ ++ ++ + − ++
AZA ++ + ++ + − +
Mel 120 CTRL ++ − + + − +
Guadecitabine ++ − + + − +
DAC ++ − + + − +
AZA ++ − + + − +
Mel 237 CTRL ++ − ++ ++ − +
Guadecitabine ++ − ++ ++ − ++
DAC ++ − ++ ++ − ++
AZA ++ − ++ ++ − +
Mel 403 CTRL ++ − + − − +
Guadecitabine ++ − + ++ + +
DAC ++ − + ++ + +
AZA ++ − + + + +
Mel 313 CTRL − − − − − −
Guadecitabine + + − ++ + ++
DAC − + − ++ + ++
AZA − − − + − −
Mel 195 CTRL − − − − − −
Guadecitabine ++ ++ − ++ + ++
DAC ++ ++ − ++ + ++
AZA − − − − + −
Mel 275 CTRL ++ − ++ − − −
Guadecitabine ++ ++ ++ ++ + ++
DAC ++ ++ ++ ++ + ++
AZA ++ + ++ ++ + ++
Mel 458 CTRL − − − ++ − −
Guadecitabine + + − ++ + ++
DAC + + − ++ + ++
AZA + − − ++ − +
Mel 599 CTRL + − − − − −
Guadecitabine + − − ++ + ++
DAC + − − ++ + +
AZA + − − ++ − +
Mel 261 CTRL + − − + − −
Guadecitabine ++ + + ++ + ++
DAC ++ + + ++ + ++
AZA + − + ++ − −
Mel 514 CTRL ++ − ++ ++ − −
Guadecitabine ++ ++ ++ ++ + +
DAC ++ ++ ++ ++ + +
AZA ++ ++ ++ ++ − +
Mel 345 CTRL ++ ++ − + − −
Guadecitabine ++ ++ + ++ + ++
DAC ++ ++ + ++ + ++
AZA ++ ++ + ++ + ++
(Continued)
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TABLE 1 | Continued
CTAs MAGE-A2 MAGE-A4 MAGE-A10 GAGE1-2 SSX1-2 SSX1-5
Mel 142 CTRL ++ ++ ++ ++ ++ ++
Guadecitabine ++ ++ ++ ++ ++ ++
DAC ++ ++ ++ ++ ++ ++
AZA ++ ++ ++ ++ ++ ++
∗RT-PCR analyses were performed on total RNA extracted from 14 melanoma cell lines either untreated (CTRL) or treated with 1µM guadecitabine, DAC or AZA.
a Intensity of RT-PCR products: −, not detectable; +, weak; ++, strong.
TABLE 2 | MFI by flow cytometry analysis of DHAs-treated melanoma cell lines∗.
HLA class Ia ICAM-1b
CTRL Guadecitabine DAC AZA CTRL Guadecitabine DAC AZA
Mel 195 10.60 41.47 52.38 23.58 35.22 91.05 115.34 69.45
Mel 313 145.62 300.27 328.83 244.41 12.71 26.89 33.14 15.23
Mel 275 39.01 106.24 110.23 87.02 139.59 118.91 171.77 138.96
Mel 346 64.50 76.60 73.80 44.90 15.4 16.00 17.60 17.70
Mel 116 151.93 245.77 267.44 173.57 54.25 87.98 93.35 75.95
Mel 120 35.20 54.40 50.60 43.80 48.10 51.70 49.20 48.80
Mel 514 408.75 471.22 425.21 405.77 50.99 66.30 63.17 46.57
Mel 142 62.07 66.48 74.43 51.95 31.21 73.20 49.75 12.03
Mel 237 33.47 40.50 33.39 27.87 33.20 28.95 32.16 39.29
Mel 403 77.28 144.77 138.48 125.06 18.96 29.84 30.55 20.76
Mel 458 47.04 90.45 97.17 53.46 15.35 24.75 26.40 10.00
Mel 345 77.38 129.51 130.41 103.22 46.55 80.97 70.10 38.54
Mel 599 57.77 64.94 70.58 47.26 23.09 24.11 32.52 20.13
Mel 261 197.84 314.62 328.04 196.78 166.63 139.78 122.40 86.94
Mean 100.60 153.40 155.80 116.30 45.80 61.50 64.80 45.70
SD 103.15 130.17 126.63 107.67 37.81 38.94 45.25 36.56
Dunn Test vs. CTRL p = 0.0004 p < 0.0001 p > 0.9999 p = 0.0252 p = 0.0013 p > 0.9999
∗Melanoma cell lines untreated (CTRL) and treated with 1µM guadecitabine, DAC or AZA were incubated with anti-human HLA class I (a) and anti-ICAM-1 (b) mAbs and
studied by flow cytometry. Data were analyzed by using Kaluza software. Mean fluorescence intensity (MFI) of cell surface staining.
TABLE 3 | MFI by flow cytometry analysis of DHAs-treated hematological tumor cell lines∗.
HLA class Ia ICAM-1b
CTRL Guadecitabine DAC AZA CTRL Guadecitabine DAC AZA
JY 323.50 601.77 670.23 539.93 152.88 193.07 235.77 149.21
KG-1a 166.12 331 350.79 365.28 18.28 48.11 45.55 23.31
Ri-1 50.62 602.54 624.65 393.37 129.28 606.86 567.30 452.94
NALM-6 43.98 502.20 475.70 300.94 114.70 602.38 576.41 475.26
Rajy 41.31 542.19 482.72 116.49 177.39 459.20 483.72 369.83
U-937 245.40 313.10 293.44 244.43 11.33 27.08 25.44 25.76
JURKAT 48.53 71.92 76.50 62.80 0.51 0.96 1.08 0.58
K562 2.17 5.75 7.36 4.26 8.96 7.54 8.76 5.05
HL-60 246.28 146.90 151.31 127.59 1.06 5.92 6.57 3.63
Daudi 0.12 0.34 0.24 0.00 26.25 77.58 107.66 78.74
Mean 116.80 31.80 313.30 215.50 64.10 202.90 205.80 158.40
SD 117.97 243.52 248.36 182.39 70.63 253.18 243.68 196.22
Dunn Test vs. CTRL p = 0.0097 p = 0.003 p > 0.9999 p = 0.0055 p = 0.0016 p = 0.8961
∗Hematological tumor cell lines untreated (CTRL) and treated with 1 µM guadecitabine, DAC or AZA were incubated with anti-human HLA class I (a) and anti-ICAM-1 (b)
mAbs and studied by flow cytometry. Data were analyzed by using Kaluza software. Mean Fluorescence intensity (MFI) of cell surface staining.ii.
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FIGURE 3 | Quantitative RT-PCR analysis of IC molecules expression in melanoma and hematological cancer cell lines treated with DHAs. Total RNA was extracted
from melanoma (A–D) and hematological cancer (E,G) cell lines, untreated (CTRL) or treated with 1 µM guadecitabine, DAC or AZA. Quantitative real-time RT-PCR
analyses were performed on retrotranscribed total RNA, utilizing CTLA-4-, PD-1-, PD-L1- and β-actin-specific primers. ICs expression was normalized to the
expression of the β-actin gene. Scatter plots represent: (i) the number of IC molecules in untreated and DHAs-treated IC-negative melanoma (A,C) and
hematological cancer (E,F) cells; (ii) the FC of IC expression in untreated vs. DHAs-treated IC-positive melanoma (B,D) and hematological cancer (G) cells. Figures
show also mean values ± SD of normalized ICs molecules (A,C,E,F) and p-value calculated by Dunn’s test between mean values of IC expression in DHAs-treated
compared to untreated cells. Each data point represents individual cell line. Solid line (black) represents gene expression value ≥1E-04 or FC expression value ≥2.
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A similar trend of IC modulation by DHAs was observed
in hematological cancer cell lines. The expression of CTLA-4-
specific mRNA was induced in 30% (3/10), 50% (5/10), and 20%
(2/10) of CTLA-4-negative hematological cancer cells treated
with guadecitabine, DAC or AZA, respectively. This induction
was stronger after treatment with guadecitabine or DAC vs.
AZA, being the mean values of CTLA-4 molecules ± SD 1.06E-
03 ± 1.53E-03, 7.25E-04 ± 1.33E-03 vs. 2.54E-04 ± 1.48E-04,
respectively (Figure 3E). Likewise, a higher frequency of PD-1
induction was detected in PD-1-negative hematological cancer
cells after treatment with both guadecitabine or DAC (44.4%,
4/9) compared to AZA treatment (22.2%, 2/9) with no differences
in the mean values of PD-1 molecules induced by all DHAs
treatments (Figure 3F).
Moreover, treatment with both guadecitabine or DAC up-
regulated (FC ≥2) constitutive levels of PD-L1 expression in
62.5% (5/8) positive hematological cancer cells, compared to
0% in AZA-treated cells (Figure 3G). Induction of PD-L1
was observed in one PD-L1-negative cell line only after DAC
treatment (Supplementary Table 14).
Statistical analysis performed on data obtained from all
investigated melanoma and hematological cancer cells showed
significant (p < 0.05) differences in levels of CTLA-4 and PD-
1 expression detected after guadecitabine and DAC treatment,
but not after AZA, compared to untreated cells (Supplementary
Tables 9, 10, 12, 13). Moreover, levels of PD-L1 expression
observed only after DAC treatment were significantly different
(p < 0.05) in both melanoma and hematological cancer cells vs.
untreated cells (Supplementary Tables 11, 14).
Comparative Analysis of the Activity of
Different DHAs in TME
Immunomodulation
The study of the immunomodulatory effects of different DHAs
was expanded by qRT-PCR analysis of changes in the expression
of selected immunostimulatory molecules (e.g., CXCL10 and
CXCL9, MICA and MICB) in melanoma (n = 14) and
hematological tumor (n = 10) cell lines treated with 1 µM
guadecitabine, DAC or AZA.
Treatment with guadecitabine or DAC vs. AZA induced
the mRNA expression of CXCL10 in 38.5% (5/13) and 30.7%
(4/13) vs. 15.4% (2/13) chemokine-negative melanoma cell lines,
with no differences in the mean values of induced CXCL10
molecules among investigated DHAs (Supplementary Table 15).
The expression of CXCL9 was induced only by DAC treatment
in 20% (2/10) chemokine-negative melanoma cells, while it
was up-regulated (FC ≥2) by treatment with guadecitabine
and DAC in 25% (1/4) and 75% (3/4) chemokine-positive
melanoma cells, respectively, compared to 0% in AZA-treated
cells (Supplementary Table 16).
Also the NK activating ligand MICB was induced/up-
regulated by guadecitabine and DAC treatment in 57.1% (8/14)
and by AZA in 14.2% (2/14), while MICA was up-regulated (FC
≥2) by guadecitabine and DAC treatment in 14.2% (2/14) and
by AZA in 7.1% (1/14) of melanoma cell lines (Supplementary
Tables 17, 18).
Similarly, in hematological tumor cell lines, treatment with
guadecitabine or DAC vs. AZA induced the mRNA expression
of CXCL10 in 50% (3/6), 66.6% (4/6) vs. 16.6% (1/6) of
chemokine-negative cells (Supplementary Table 19), with a
mean values ± SD of induced CXCL10 molecules of 2.41E-
02± 2.95E-02 and 2.52E-02± 4.19E-02 vs. 4.50E-03± 4.50E-03,
respectively; while the expression of CXCL9 was induced in 75%
(6/8), 75% (6/8) vs. 25% (2/8) of guadecitabine- or DAC- vs.
AZA-treated cells, respectively (Supplementary Table 20), with
no differences in the mean values of CXCL9 molecules induced
by all DHAs treatments.
No differences were observed in the number of positive
hematological tumor cell lines in which CXCL10, CXCL9,
MICA and MICB expression was up-regulated (FC ≥2) by all
investigated DHAs treatments (Supplementary Tables 19–22).
Statistical analysis performed on data obtained from all
investigated melanoma cells showed significant differences
(p < 0.05) in levels of expression of all immunostimulatory
molecules after guadecitabine and DAC treatment
(Supplementary Tables 13–16), but not after AZA exposure,
compared to untreated cells.
Conversely, data from all hematological cancer cells showed
significant (p < 0.005) differences in levels of CXCL9 and
MICA expression only after guadecitabine and DAC treatment
vs. untreated cells; while significant (p < 0.05) differences in
levels of CXCL10 and MICB expression were observed only after
AZA treatment, compared to untreated cells (Supplementary
Tables 19–22).
Comparative Analysis of Anti-viral Genes
Expression in Melanoma Cell Lines
Treated With Different DHAs
To compare the immunomodulatory activity of first and
next generation DHAs, relative quantitative real-time RT-PCR
analyses for HERVs expression were performed on 14 melanoma
and 10 hematological cancer cell lines, respectively, and for
ISGs expression on 14 melanoma cell lines, treated with 1 µM
guadecitabine, DAC or AZA.
An up-regulation (FC ≥2) of the expression levels of 8 HERV
genes was observed with a higher frequency in guadecitabine-
or DAC- vs. AZA-treated melanoma cells: 21.4% and 7.1% vs.
0% (Syncytin-1), 28.5% and 35.7% vs. 14.2% (Syncytin-2), 35.7%
and 57.1% vs. 7.1% (ENV-T), 42.8% and 42.8% vs. 0% (ERV9-
1), 35.7% and 42.8% vs. 35.7% (ENV-MER34), 78.5% and 78.5%
vs. 28.5% (ERV-FXA34), 21.4% and 64.2% vs. 0% (ENV-Fb1)
and 28.5% and 50% vs. 7.1% (ENV-Fc2). Also in hematological
cancer cell lines, HERVs up-regulation (FC ≥2) was observed
with a higher frequency in guadecitabine- or DAC- vs. AZA-
treated cells being 10% and 10% vs. 10% (Syncytin-1), 20% and
20% vs. 10% (Syncytin-2), 60% and 60% vs. 30% (ENV-T), 60%
and 60% vs. 20% (ERV9-1), 50% and 60% vs. 20% (ENV-MER34),
10% and 10% vs. 0% (ENV-FXA34), 40% and 40% vs. 20% (ENV-
Fb1) and 80% and 80% vs. 30% (ENV-Fc2). FC of investigated
HERVs expression in DHAs-treated vs. untreated melanoma
and hematological tumor cells are illustrated in Figures 4A,B,
respectively.
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FIGURE 4 | Analysis of anti-viral genes expression in melanoma cell lines treated with different DHAs. Total RNA was extracted from 14 melanoma (A) and 10
hematological cancer (B) cell lines treated with 1 µM guadecitabine (gray), DAC (pink) or AZA (green). Quantitative real-time RT-PCR analyses were performed on
retrotranscribed total RNA. Box plots represent FC of HERV expression in DHAs-treated vs. untreated melanoma (A) and hematological cancer (B) cell lines and of
ISG expression in DHAs-treated vs. untreated melanoma cells (C). Figure shows standard deviation, median value (–), 25th Percentile, 75th percentile. Each data
point represents individual cell line. Solid line (black) represents a FC expression value ≥2.
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Consistently, 18 out of 21 investigated ISGs were up-regulated
(FC ≥2) with a higher frequency in melanoma cells treated with
guadecitabine or DAC, compared to AZA. In detail, ISGs were
up-regulated in 8 and 8 vs. 2 (DDX58); 7 and 6 vs. 3 (IFIT1); 7
and 5 vs. 1 (IFIT2); 1 and 2 vs. 0 (JAK1); 1 and 0 vs. 0 (JAK2); 7
and 3 vs. 3 (STAT1); 11 and 11 vs. 6 (IFI27); 8 and 8 vs. 4 (IFI6);
7 and 8 vs. 3 (OAS1); 10 and 11 vs. 5 (OAS2); 11 and 13 vs. 5
(OASL); 9 and 10 vs. 3 (IRF7); 8 and 7 vs. 4 (IRF9); 12 and 12 vs. 5
(IFITM1); 4 and 5 vs. 2 (IFITM3); 8 and 9 vs. 1 (MX1); 8 and 8 vs.
6 (MX2); 10 and 12 vs. 3 (ISG15); 9 and 9 vs. 5 (ISG20); 5 and 4 vs.
4 (IFI44) and 9 and 10 vs. 7 (IFI44L) melanoma cells, treated with
guadecitabine or DAC vs. AZA, respectively. FC of investigated
ISGs expression in DHAs-treated vs. untreated melanoma cells
are illustrated in Figure 4C.
DISCUSSION
The demonstrated immunomodulatory activity of DHAs, which
improves immunogenicity and immune recognition of cancer
cells, results in priming and sensitizing the host immune
response to immunotherapies. In light of these considerations,
several clinical studies are investigating the combination
of DHAs with different IC blocking mAbs in tumors of
different histotype. To optimize the therapeutic efficacy of
these new promising combination therapeutic strategies, we
performed a comparative study of the immunomodulatory
properties of selected clinically approved DHAs, AZA and
DAC, and of the next generation DHA, guadecitabine, on
human melanoma and hematological cancer cell lines, to
identify the best epigenetic partner to be combined with
immunotherapy.
The first evidence emerging from our results is a different
hypomethylating effect of investigated DHAs on tumors of
different histotypes. The highest LINE-1 global demethylation
is achieved with guadecitabine in both melanoma and
hematological cancer cell lines. A different hypomethylating
effect between DHAs was already discussed in AML cells
(Flotho et al., 2009; Hollenbach et al., 2010; Srivastava et al.,
2014), suggesting the distinction of investigated DHAs as
non-equivalent agents.
Different data support the role of epigenetic compounds
in facilitating immunological targeting of cancer cells
due to their ability to modulate different molecules and
pathways involved in the interplay between tumor cells and
the immune system (Sigalotti et al., 2014). Based on this
evidence, we demonstrate the higher immunomodulatory
activity of guadecitabine or DAC, compared to AZA, in
reverting the CTA-negative phenotype without differences
among histotypes analyzed. In particular, the higher levels
of CTAs expression observed after guadecitabine or DAC
treatment vs. AZA, represent an important benefit for
immune recognition of cancer cells, as CTAs are able to
induce both humoral and cell-mediated immune responses
(Sigalotti et al., 2005), thus representing ideal targets for tumor
immunotherapeutic approaches. This immunomodulatory
property of guadecitabine or DAC could render tumor cells
more susceptible to vaccination-stimulated CTA-specific
immune responses, and more generally to CD8+ T cell
specific recognition. A stronger immunomodulatory effect by
guadecitabine or DAC vs. AZA treatment is observed also
in the up-regulation of both HLA class I antigens, playing a
central role in the presentation of TAA peptides to CTL, and
of the co-stimulatory molecule, ICAM-1, allowing an increased
recognition of cancer cells and promoting the activation of T
cells.
Noteworthy, in addition to the above reported effects
on adaptive immunity by DHAs, recent data indicated that
epigenetic drugs may be exploited to allow the tumor cells
eradication by innate immune system (Kima et al., 2014; Sigalotti
et al., 2014). In this context, the expression of the NKG2DL
MICB on melanoma cells induced only by guadecitabine and
DAC treatment, could contribute to the immune recognition of
transformed cells and accordingly, to their apoptosis.
Anti-tumor immunity within the TME can be supported by
immune-stimulatory cytokines, such as CXCL9 and CXCL10,
involved in the recruitment of immunological infiltrates at tumor
site. A positive modulation of these pro-inflammatory Th1
cytokines by DHAs was previously described in ovarian cancer
(Peng et al., 2015) and in epithelial cancer cell lines (Wolff et al.,
2017; Lai et al., 2018); in this respect, our results underline the
strongest effect of guadecitabine and DAC compared to AZA in
the modulation of these cytokines, in both investigated tumor
histotypes, suggesting their major contribute to the development
of anti-tumor immune response.
Epigenetic activation of immune response has been recently
demonstrated also through the IFN pathway signaling, upstream
of antigen processing and presentation genes machinery
(Chiappinelli et al., 2017). In detail, DAC and AZA primed
ISGs expression in ovarian and colon cancer cells through
the activation of double strand RNA derived from HERVs.
Our study confirms these data in melanoma and hematological
cancer cells, but also demonstrates that guadecitabine and DAC,
compared to AZA, up-regulate a higher “viral mimicry” state
that could eventually increase immune response. In addition,
DNA demethylation offers the possibility to restore and/or
to up-regulate the immunogenic potential of cancer cells,
making them better targets for immunotherapeutic approaches.
In this context, an important way in which DHAs may
sensitize tumor cells to IC blocking therapy is through the
up-regulation of immune tolerance ligands (Wrangle et al.,
2013). Targeting of CTLA-4 or PD-1/PD-L1 molecules has
profoundly improved the clinical management of advanced
disease in a wide range of solid malignancies (Hu-Lieskovan
and Ribas, 2017). In line with these evidence, we demonstrate
that guadecitabine or DAC, compared to AZA, strongly up-
regulate the IC mRNA expression in all investigated tumor
histotypes.
The translational relevance of the immunomodulatory
activities of DHAs in cancer is sustained by the results
from our previous studies, in a syngeneic mouse tumor
model, demonstrating how guadecitabine or DAC were able
to sensitize tumor cells to the anti-tumor activity of CTLA-
4 blockade, inducing a significantly stronger tumor growth
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reduction compared to treatment with single agents (Covre et al.,
2015a,b). The immunologic aspect of the anti-tumor effects
induced by DHAs in combination with IC blocking therapy was
demonstrated by the highest degree of CD3 infiltrating T cells,
including both CD8+ and CD4+T cells, detected in tumors from
mice treated with the combination regimen (Covre et al., 2015b).
Comprehensively, this study shows that guadecitabine has
similar immunomodulatory effects to DAC and both these
compounds work better compared to AZA, identifying these
two drugs as optimal partners to potentiate the anti-tumor
activity of different immunotherapeutic approaches, not only in
solid but also in hematological tumors. The higher resistance of
guadecitabine to degradation by cytidine deaminase, supports
its promising clinical activity and acceptable safety profile, by
prolonging its in vivo exposure (Roboz et al., 2018). Along
this line, the ongoing NIBIT-M4 clinical study, testing the
immunologic and clinical efficacy of guadecitabine combined
with the anti-CTLA-4 mAb, ipilimumab, in metastatic melanoma
patients (Di Giacomo et al., 2018), will provide further
support to the therapeutic potential of epigenetically based
immunotherapy.
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